Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETIC ACID W/ HYDROCORTISONE vs AEROSEB-HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Treatment of superficial bacterial infections of the external auditory canal (otitis externa) and associated inflammation.
FDA-approved for the treatment of eczematous dermatitis, atopic dermatitis, and other glucocorticoid-responsive dermatoses complicated by fungal or bacterial infections
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
Acetic acid is metabolized via the Krebs cycle to carbon dioxide and water. Hydrocortisone is primarily metabolized in the liver.
Hydrocortisone is primarily hepatic via CYP3A4; iodoquinol is not extensively metabolized, with partial glucuronidation and enterohepatic circulation.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid: negligible binding.
90-95% (albumin and corticosteroid-binding globulin).
Hydrocortisone: Vd ~0.3–0.5 L/kg (systemic); topical application results in negligible systemic distribution.
0.4-0.6 L/kg; indicates distribution into total body water and tissues.
Topical: ~1–5% of hydrocortisone absorbed through intact skin; higher with inflamed skin or occlusion. Acetic acid: negligible systemic absorption.
Oral: 80-90%; Intramuscular: 100%; Intravenous: 100%.
No dose adjustment required for acetic acid. Hydrocortisone is minimally affected by renal impairment; no specific adjustment recommended.
No adjustment required for topical application. Systemic absorption is minimal; however, in severe renal impairment (GFR <30 m L/min), use caution due to potential systemic corticosteroid effects.
No dose adjustment required for acetic acid. For hydrocortisone, use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reducing frequency or dose, though no specific guidelines exist.
No specific adjustment for topical use. In Child-Pugh C cirrhosis, consider the risk of systemic corticosteroid accumulation; use with caution.
Safety and efficacy not established in pediatric patients; use not recommended.
Children >2 years: Apply a thin film to affected area twice daily for up to 7 days. Avoid prolonged use, occlusion, or application to large body surface areas. Safety in children <2 years not established.
No specific dose adjustment required. Use caution due to potential skin atrophy and systemic absorption; limit duration to minimum effective course.
Elderly patients: Use the lowest effective duration and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. Apply sparingly to limited areas.
Not applicable.
None
For otic use only; not for ophthalmic or systemic use.,Prolonged use may lead to fungal or bacterial superinfection.,Discontinue if irritation or sensitization develops.
Prolonged use may lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome, and hyperglycemia.,Risk of secondary infection due to immunosuppression.,Local adverse reactions such as skin atrophy, striae, and perioral dermatitis.,Avoid use in diaper area or under occlusive dressings.
Hypersensitivity to any component.,Viral or fungal infections of the external ear (e.g., herpes simplex, varicella).,Perforated tympanic membrane (risk of ototoxicity).
Hypersensitivity to any component (hydrocortisone, iodoquinol, or sulfites).,Viral or fungal infections without appropriate antimicrobial coverage.,Immunocompromised patients (systemic use relative).,Pregnancy (category C, use only if benefit outweighs risk).
No clinically relevant food interactions. No specific dietary restrictions.
No clinically significant food interactions are reported for topical hydrocortisone/pramoxine. No dietary restrictions necessary.
Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed with topical use. Systemic absorption is minimal with small-area application. Avoid prolonged use on large areas, occlusive dressings, or high-potency steroids. Acetic acid has no known teratogenic risk.
FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adrenal suppression with prolonged use; avoid high doses and prolonged exposure.
Minimal systemic absorption of topical hydrocortisone and acetic acid; unlikely to affect the breastfed infant. Use on limited areas, avoid application to breast or nipple area. M/P ratio not established.
Present in breast milk in low concentrations. M/P ratio not determined. Use with caution, especially with high doses or prolonged treatment; risk of infant adrenal suppression theoretical.
No dosing adjustments required for pregnancy. Use lowest effective dose for shortest duration to minimize systemic absorption.
No standard dose adjustments required for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid high-dose or prolonged use in pregnancy.
Combination otic suspension for external otitis. Ensure tympanic membrane is intact before use; perforation risks ototoxicity. Shake well before instillation. Use for no longer than 10 days to avoid fungal overgrowth or adrenal suppression. Warm bottle in hands to avoid caloric vertigo. Contraindicated in viral or fungal infections of the ear canal.
AEROSEB-HC is a combination aerosol foam containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% for topical use. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly in anogenital areas. The foam formulation enhances penetration and is less messy than ointments. Advise patients to avoid contact with eyes and mucous membranes. Use with caution in patients with skin infections or atrophy. Prolonged use in intertriginous areas may increase risk of local and systemic adverse effects.
For ear use only. Do not swallow or put in eyes.,Lie on side with affected ear upward for 5 minutes after instillation.,Keep ear clean and dry while using the medication.,Complete full course even if symptoms improve.,Do not use if you have a perforated eardrum; seek medical evaluation first.,Shake the bottle well before each use.
Apply a small amount to the affected area as directed, usually 2-4 times daily.,Do not cover the area with bandages or dressings unless instructed by your doctor.,Avoid use on broken skin, open wounds, or infected areas unless specifically prescribed.,Do not use for more than 2 weeks without medical supervision, especially in the anogenital region.,If symptoms do not improve or worsen, contact your healthcare provider.,Keep away from eyes, mouth, and other mucous membranes.,Wash hands after applying unless treating hands.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETIC ACID W/ HYDROCORTISONE vs AEROSEB-HC, answered by our medical review team.
ACETIC ACID W/ HYDROCORTISONE is a Corticosteroid that works by Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.. AEROSEB-HC is a Topical Corticosteroid that works by AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETIC ACID W/ HYDROCORTISONE and AEROSEB-HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETIC ACID W/ HYDROCORTISONE is: 1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.. The standard adult dose of AEROSEB-HC is: AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETIC ACID W/ HYDROCORTISONE and AEROSEB-HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETIC ACID W/ HYDROCORTISONE is classified as Category D/X. Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed wit. AEROSEB-HC is classified as Category C. FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.